Julie Dunn, MD
Internal Medicine · Murfreesboro, TNNPI 1568453207
Payments from drug & device makers
Across 163 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$991
- GSK$266
- AbbVie$181
- Abbott$148
- Amgen$135
- Pfizer$134
- plus $987 from 24 others
What the payments were for
- Food & beverage$2,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $991 |
| GSK | 15 | $266 |
| AbbVie | 6 | $181 |
| Abbott | 6 | $148 |
| Amgen | 8 | $135 |
| Pfizer | 7 | $134 |
| Astellas Pharma US Inc | 5 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $114 |
| Lilly USA, LLC | 6 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Dynavax Technologies Corporation | 3 | $65 |
| AstraZeneca | 3 | $51 |
| Exact Sciences | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Shield Therapeutics Inc | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$2,842 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $77,814 |
| EliquisApixaban | 40 | $42,396 |
| JanuviaSitagliptin Phosphate | 26 | $22,656 |
| LinzessLinaclotide | 21 | $22,131 |
| MounjaroTirzepatide | 19 | $20,622 |
| TradjentaLinagliptin | 16 | $18,357 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $18,090 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $17,527 |
| MyrbetriqMirabegron | 19 | $12,960 |
| Atorvastatin Calcium | 563 | $6,323 |
| Levothyroxine Sodium | 400 | $5,483 |
| PremarinEstrogens, Conjugated | 11 | $5,368 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,374 |
| Omeprazole | 175 | $3,055 |
| Losartan Potassium | 209 | $2,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $991 | $77,81474 claims |
| PfizerEliquis, Premarin | $134 | $47,76551 claims |
| AbbVieLinzess, Synthroid | $181 | $23,41242 claims |
| MerckJanuvia | $11 | $22,65626 claims |
| Lilly USA, LLCMounjaro | $105 | $20,62219 claims |
| GSKTrelegy Ellipta | $266 | $17,52715 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $12,96019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Murfreesboro
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.